angiotensin ii at1-receptor

L162389 is an orally active and potent angiotensin II receptor antagonist with a balanced affinity for AT1 and AT2 receptor subtypes that stimulates the conversion of phosphatidylinositol.

Losartan potassium (DuP-753 potassium), an Angiotensin II Receptor Blocker, selectively and competitively inhibits the binding of angiotensin II to the angiotensin I (AT1) receptor.

Losartan (DuP-753) is an angiotensin II receptor antagonist.

Olmesartan Medoxomil (Benicar) is an angiotensin II type 1 receptor blocker that is used to manage hypertension.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist (IC50: 0.26 nM). Upon hydrolysis to candesartan during gastrointestinal absorption, it selectively competes with angiotensin II for binding to the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation.

Eprosartan Mesylate (SKF-108566J) is a competitive and reversible Angiotensin II Receptor Blocker.

Angiotensin II human acetate (DRVYIHPF acetate) is a vasoconstrictor that mainly acts on the AT1 receptor.

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.

Losartan Carboxylic Acid (E-3174), a potent AT1 antagonist (Kis: 0.57 nM, rat; 0.67 nM, human), produces a depressor response and vasodilatation. As a metabolite of losartan, it is more potent than losartan in blocking angiotensin II-induced responses in vascular smooth muscle cells.

(Sar¹)-Angiotensin II acetate, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. It binds to brain membrane-rich particles, with a Kd of 2.7 nM. It can stimulate protein synthesis and cell growth in embryonic chick myocytes.

TRV120027 TFA is a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R) and engages ß-arrestins while blocking G-protein signaling.

Angiotensin II (3-8), human (TFA), is an angiotensin AT1 receptor agonist with reduced activity.

Losartan D4, the deuterium-labeled version of Losartan, functions as an angiotensin II receptor antagonist. It inhibits the interaction between angiotensin II and AT1 receptors by competing for binding, achieving an IC50 value of 20 nM.

TD-0212 is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).

TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2.

Buloxibutid (AT2 receptor agonist C21) is a novel and selective small molecule angiotensin II AT2 receptor agonist, exhibiting Ki values of 0.4 nM and 10 μM for AT2 and AT1 receptors, respectively.

Candesartan (CV 11974) is an angiotensin II receptor blocker widely used in the treatment of hypertension and heart failure.

BMS-248360 is a potent, orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptors, respectively. BMS-248360 demonstrates hypertensive effects[1].

Elisartan is a non-peptide pro-drug of angiotensin II AT1 receptor antagonist HN-12206. It also shows anti-hypertension activities.

Nitrosoglutathione (GSNO) is an endogenous transnitrosation donor involved in S-nitrosation of a variety of cellular proteins. GSNO, an exogenous NO donor and substrate of rat alcohol dehydrogenase class III isoenzyme, inhibits cerebral angiotensin II-dependent and -independent AT1 receptor responses.

GA 0113 is an effective orally active antagonist of the angiotensin II (Ang II) AT1 receptor. It inhibits the hypertensive response induced by Ang II, with an ID50 of 0.032 mg kg, and dose-dependently increases plasma renin activity for up to 48 hours.

1H-1-ethyl Candesartan Cilexetil is a process-related impurity in the bulk synthesis of candesartan cilexetil, which is a potent, long-acting and selective angiotensin II type 1 receptor (AT1) antagonist.

Fimasartan (BR-A-657) is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials.